Advanced Enzyme Technologies Management Guidance Tracker

8 forward-looking guidance items tracked across 2 quarters.

Growth

Q3 FY26Long-term revenue growth of 13-15%Tracked

Management reiterated expectation of double-digit revenue growth on a continuous basis over 3-5 years, though ride will be roller-coaster.

Q4 FY26EU approval for anti-inflammatory product expected in FY27Tracked

The product filed two years ago is anticipated to receive EU approval this year, providing exclusivity for 5-10 years.

Margins

Q3 FY26Tariff impact on EBITDA margin ~1%Active

Worst-case tariff impact on EBITDA margin expected to be around 1% (down from earlier 2% estimate), with efforts to pass on costs to US customers.

Q4 FY26EBITDA margin to remain around 31%Active

Margins expected to be steady with possible 1-2% variability due to cost pressures.

Capex

Q3 FY26New R&D center commissioning by Q2 FY27Tracked

The new R&D center in Nashik, focusing on strain development, protein, and fermentation, is expected to be commissioned by end of second quarter of next financial year.

Q4 FY26New R&D center operational in H2 FY27Tracked

The new R&D center in Nashik will be fully operational in the second half of FY27, boosting product development capacity threefold.

Revenue

Q3 FY26B2C business to generate ₹1-1.5 crore in FY26Active

The newly separated B2C subsidiary is expected to achieve small sales of around ₹1-1.5 crore by end of current fiscal year.

Q4 FY26Double-digit revenue growth in FY27Active

Management expects double-digit growth for FY27, driven by all segments including human, animal, and food.